



QIAGEN's Conference Call Acquisition of artus GmbH

A Leading OEM Supplier of Molecular Diagnostic
Assay Solutions to Leading Diagnostic Companies

May 31, 2005

QIAGEN Conference Call Acquisition of artus GmbH



May 31, 11:00 am EDT, 16:00 GMT, 17:00 MET

Conference Call Outline:

1) 10 min Presentation (Companies, Rationale, Deal Structure, Guidance)

Peer M. Schatz, CEO

Roland Sackers, CFO

Dr. Noel Doheny, VP QIAGEN Solutions for Molecular Diagnostics

Dr. Solveigh Mähler, Director IR

2) 20 min Q&A session



artus. A leading supplier of molecular diagnostic assays (tests, consumables) to diagnostic companies


Certain of the statements contained in this presentation may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products and markets and operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations), variability of operating results, the commercial development of the DNA sequencing, genomics and synthetic nucleic acid-related markets, as well as the nucleic acid-based molecular diagnostics and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's products (including seasonal fluctuations), difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products from competitors, and the integration of acquisitions of technologies and businesses. For further information, refer to the discussion in reports that QIAGEN has filed with the U.S. Securities and Exchange Commission (SEC).

The following slides may contain certain summary information about QIAGEN N.V.'s operating income, net income, and earnings per share, which information is presented on a "non-GAAP financial measures" basis rather than in accordance with U.S. generally accepted accounting principles ("GAAP"). Please review QIAGEN's recent press releases for information on the company's operating income, net income, and earnings per share for specific periods presented on a GAAP basis. Such GAAP-basis information will also be contained in the company's reports on Form 20-F and 6-K to be filed with or furnished to the U.S. Securities and Exchange Commission and which are available on QIAGEN's homepage under www.QIAGEN.com.

Molecular Diagnostics (20% of sales):

- Reliable: partnering since 1992, now great growth!
- Focused: > \$70 million in sales in diagnostics
- Delivering: major (regulated) pipeline in 2005
- Investing: over 100 clinical trials using QIAGEN
- Investing: over 50 clinical trials involving PreAnalytiX
- Investing: over 15 partners in diagnostics (!)
 - Q1: Roche
 - Q1: Veridex (J&J)
 - Q2: Beckman
- Investing: new, separate sales and marketing force
- Investing: leading/active in regulatory initiatives

Setting Standards – Great Potential



Design of test and consumables



Instrument detects assay results




- Established leader in PCR-based diagnostic assay design
- \$11 million in forecasted sales 2005, fast growing
- Portfolio with > 60 assays, >30 CE marked products
 - infectious pathogen assays (virus, bacteria, ...)
 - pharmacogenomics assays
 - Veterinary assays
- Broad technology and IP portfolio, Dx PCR license
- OEM customers (Abbott and others)
- artus-designed assays for different instruments including LightCycler, TaqMan, RotorGene and EP
- Fast, leading: e.g. first to develop SARS test

artus GmbH
Leading OEM Supplier to Diagnostic Companies





| | |
|--|--|
| Life Science Research | Molecular Diagnostics |
| | |
| Technology Synergy! | |
| | |
| Applied Biosystems, Roche Applied Science, Bio-Rad, Stratagene, Cepheid etc etc. | Abbott Laboratories (Celera Diagnostics), Roche Diagnostics, etc. etc. |



Benefits for OEM partners


- Broadens menu = broader market
- Optimized integration
- Broad IP portfolio
- No instrument dependency
- Assay development is scarce resource
- Objectivity – loyalty

Win/Win situation for QIAGEN partners!



- Increase of QIAGEN's value as OEM partner in MDx
QIAGEN can provide preanalytical solution plus linked assay
- Proven compatibility
- technology and expertise leader
- regulatory expertise
- Perfect fit to QIAGEN's leading PCR technology portfolio
- Strong synergies in operations
good track record in joint projects

**Combination Catalyzes Value of QIAGEN's
Preanalytical Solution for our Partners**



Purchase Price

- Approximately US\$ 27.6 in cash upfront
- Approximately US\$ 11.6 million held in escrow until milestones achieved
- Upfront and escrow (US\$ 39.2 million) represent a multiple of approximately 2.6x forward net sales

Acquisition-related charges

- approx. US\$ 2.0 – 3.0 million pre-tax
- mostly in Q2 2005
- consisting primarily of in-process R&D charges (with no underlying tax basis)
- approx. US\$ 0.02 diluted earnings per share

Great Asset – Attractive Valuation



| | 2005 | |
|-----------------------|--------|--------|
| | Q3 | Q4 |
| Increase in Net sales | \$2 M | \$3 M |
| Changes in EPS | \$0.00 | \$0.00 |

Note: in reference to guidance given on May 2, 2005.



Integration

- Production: Leverage GMP infrastructure at QIAGEN
- Marketing: Full integration into QIAGEN's diagnostics team
- Sales: Integration into QIAGEN's diagnostics sales force
- R&D – Hamburg, Germany (diagnostic assays),
Hilden, Germany (preanalytical)
Germantown, USA (assay support)
- Administration: Integration into QIAGEN

Focus on Integration – Exploiting Synergies



| In US\$ millions unless indicated | 2006 |
|-----------------------------------|-------------|
| Net sales | 15.0 |
| Net income | 1.5 - 2.0 |
| EPS in US\$ | 0.01 - 0.02 |

Accretive in 2006 due to operational synergies:

- Perfect fit to QIAGEN's product portfolio (PCR, HLA)
- Good track record in R&D
- Highly synergistic in production (PCR reagents)
- Highly synergistic in S&M

Creating Synergies – Accretive Deal



Questions & Answers

Due to time restrictions we would like to ask for a maximum of TWO questions per caller.